

Received SEC **NASDAQ**  
THE NASDAQ OMX GROUP

SEP 16 2014

Washington, DC 20549

William Slattery, CFA  
Vice President  
Listing Qualifications

CERTNAS  
001-36624

By Electronic Mail

September 16, 2014



14008037

Mr. Jeffrey Thomas  
Chief, IT Services  
Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549

Dear Mr. Thomas:

This is to certify that on September 16, 2014 The Nasdaq Stock Market (the "Exchange") received from rEVO Biologics, Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

Common Stock, par value \$0.01 per share

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

*William Slattery*